EUVIMEDEUVIMED entdecken
Crossref

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

Michele Zazzara, Arjan Nazaraj, Marcello Scarcia, Giuseppe Cardo, Roberto Carando, Giuseppe Mario Ludovico

Urologia Internationalis · 2023 · 107 (1) · 64-71

DOI: 10.1159/000520630 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, online erschienen am 21.12.2021. Verfasst von Michele Zazzara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti, Italy. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although TURB of tumor (TURBT) by itself can eradicate a non-muscle-invasive bladder cancer (NMIBC) completely, these tumors commonly recur and can progress to MIBC. It is, therefore, necessary to consider adjuvant therapy in most patients. The primary objective of the present study was to report our experience with EMDA/MMC and BCG, considering efficacy, progression, and recurrence, as adjuvant therapy in NMIBC patients; the secondary objective was to assess the efficacy of EMDA/MMC versus BCG as a comparative treatment.

Methods

Between April 2016 and February 2020, a series of 216 patients, with a diagnosis of intermediate- and high-risk NMIBC after TURBT, underwent adjuvant intravesical therapy. In 26 cases with a failure of the treatment, in patients unfit and unwilling for radical cystectomy, a repeated intravesical therapy was performed (2 had a twice repetition). Out of 244 adjuvant therapies, 140 EMDA/MMC and 104 BCG treatments were done. The following data were collected for each patient: baseline demographics and clinical data and perioperative and postoperative data. Overall patients’ adjuvant intravesical therapies were included in a prospectively maintained institutional database, and a retrospective chart review was performed. We collected data on 2 main outcomes, recurrence-free survival (defined as a negative cystoscopy, cytology, and/or histology at the evaluation time point) and progression-free survival (defined as a negative cystoscopy or a nonprogressive tumor recurrence).

Results

The NMIBC progression rate was higher in BCG than EMDA/MMC but not statistically significant (respectively, 4.2% vs. 2.5%; p = 0.703). In the overall population, the risk of NMIBC recurrence was higher after BCG than EMDA/MMC (p = 0.025). In the subgroups of 59 paired patients with similar characteristics, no difference was observed between groups in NMIBC progression and recurrence.

Conclusions

Our findings suggest that EMDA/MMC and BCG are safe and reproducible approaches as adjuvant treatment in NMIBC. EMDA/MMC permits to achieve a fine oncological management as adjuvant treatment in NMIBC, which is not less than that obtained with BCG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsHumansMitomycinBCG VaccineRetrospective StudiesNeoplasm Recurrence, LocalAdjuvants, ImmunologicImmunotherapyAdministration, IntravesicalNeoplasm Invasiveness

Stichwörter der Autor:innen

Bacillus Calmette-GuérinBladder cancerElectromotive drug administrationIntravesical treatmentNon-muscle-invasive bladder cancer

Substanzen

MitomycinBCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti, Italy.
  • Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Clinica Luganese Moncucco, Lugano, Switzerland.
  • Clinica S. Anna, Sorengo, Switzerland.
  • Clinica S. Chiara, Locarno, Switzerland.

Zitieren

APA

Zazzara, M., Nazaraj, A., Scarcia, M., Cardo, G., Carando, R., & Ludovico, G. M. (2023). Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer. Urologia Internationalis, 107(1), 64-71. https://doi.org/10.1159/000520630

Vancouver

Zazzara M, Nazaraj A, Scarcia M, Cardo G, Carando R, Ludovico GM. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer. Urologia Internationalis. 2023;107(1):64-71. doi:10.1159/000520630

BibTeX
@article{Zazzara2023,
  author = {Zazzara, Michele and Nazaraj, Arjan and Scarcia, Marcello and Cardo, Giuseppe and Carando, Roberto and Ludovico, Giuseppe Mario},
  title = {Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer},
  journal = {Urologia Internationalis},
  year = {2023},
  volume = {107},
  number = {1},
  pages = {64--71},
  doi = {10.1159/000520630}
}
Kostenlos starten →